You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 110 No. 2, February 1992 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLE
 This Article
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988

M. Diener-West, B. S. Hawkins, J. A. Markowitz and A. P. Schachat
Wilmer Ophthalmological Institute, Johns Hopkins University, Baltimore, Md.

With the use of data published during the period from 1966 through 1988, a pooled analysis (meta-analysis) of 5-year mortality rates among patients who had an eye enucleated for choroidal melanoma was performed to provide a more robust estimate of this rate than could be obtained from any single study. The literature concerning mortality following a diagnosis of choroidal melanoma has been reviewed systematically and described in a separate article. Of 76 reports published from 1966 through 1988, 29 were excluded from the meta-analysis because there were no cases treated by enucleation alone, mortality was not reported by time from enucleation, fewer than 10 cases were reported, or 5-year mortality rates were not reported or derivable from the data presented. Ten additional reports were excluded because they were based on data for the same set of patients as another article in the series. Of the remaining 37 reports, 29 contained data for patients with tumors of varying sizes that could not be separated into subgroups based on the size of the tumor at the time of treatment. The remaining eight articles reported 5-year mortality rates by tumor size, specifically for small, medium, or large tumors. The combined weighted estimates of 5-year mortality rates following enucleation were 16% for small tumors (95% confidence interval [CI]: [14%, 18%]), 32% for medium tumors (95% CI: [29%, 34%]), and 53% for large tumors (95% CI: [50%, 56%]). Different methods of pooling the data yielded consistent estimates for all three tumor size categories.(ABSTRACT TRUNCATED AT 250 WORDS)

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Oral Picropodophyllin (PPP) Is Well Tolerated In Vivo and Inhibits IGF-1R Expression and Growth of Uveal Melanoma
Economou et al.
IOVS 2008;49:2337-2342.
ABSTRACT | FULL TEXT  

Hepatic Arterial Chemoembolization for Management of Metastatic Melanoma
Sharma et al.
Am. J. Roentgenol. 2008;190:99-104.
ABSTRACT | FULL TEXT  

A Role for EZH2 in Silencing of IFN-{gamma} Inducible MHC2TA Transcription in Uveal Melanoma
Holling et al.
J. Immunol. 2007;179:5317-5325.
ABSTRACT | FULL TEXT  

Reduced expression of autotaxin predicts survival in uveal melanoma
Singh et al.
Br. J. Ophthalmol. 2007;91:1385-1392.
ABSTRACT | FULL TEXT  

The Investigators' Perspective on the Collaborative Ocular Melanoma Study
Fine and Hawkins
Arch Ophthalmol 2007;125:968-971.
FULL TEXT  

Correlation of Heterogeneity for Chromosome 3 Copy Number with Cell Type in Choroidal Melanoma of Mixed-Cell Type
Sandinha et al.
IOVS 2006;47:5177-5180.
ABSTRACT | FULL TEXT  

The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma: V. Twelve-Year Mortality Rates and Prognostic Factors: COMS Report No. 28
Collaborative Ocular Melanoma Study (COMS) Group
Arch Ophthalmol 2006;124:1684-1693.
ABSTRACT | FULL TEXT  

A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma
Schmittel et al.
Ann Oncol 2006;17:1826-1829.
ABSTRACT | FULL TEXT  

Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma
Kiewe et al.
Ann Oncol 2006;17:1830-1834.
ABSTRACT | FULL TEXT  

Vascular Endothelial Growth Factor A in Eyes With Uveal Melanoma
Missotten et al.
Arch Ophthalmol 2006;124:1428-1434.
ABSTRACT | FULL TEXT  

18-Fluorine-labelled 2-deoxy-2-fluoro-D-glucose positron emission tomography/computed tomography standardised uptake values: a non-invasive biomarker for the risk of metastasis from choroidal melanoma
Finger et al.
Br. J. Ophthalmol. 2006;90:1263-1266.
ABSTRACT | FULL TEXT  

Long term ultrasonic follow up of choroidal naevi and their transformation to melanomas
Kaiserman et al.
Br. J. Ophthalmol. 2006;90:994-998.
ABSTRACT | FULL TEXT  

Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients
Peters et al.
Ann Oncol 2006;17:578-583.
ABSTRACT | FULL TEXT  

The Insulin-Like Growth Factor-I Receptor Inhibitor Picropodophyllin Causes Tumor Regression and Attenuates Mechanisms Involved in Invasion of Uveal Melanoma Cells
Girnita et al.
Clin. Cancer Res. 2006;12:1383-1391.
ABSTRACT | FULL TEXT  

Monosomy 3 Predicts Death but Not Time until Death in Choroidal Melanoma
Sandinha et al.
IOVS 2005;46:3497-3501.
ABSTRACT | FULL TEXT  

REFERENCES
JOURNAL OF THE ICRU 2004;4:165-175.
FULL TEXT  

Identification of monosomy 3 in choroidal melanoma by chromosome in situ hybridisation
Sandinha et al.
Br. J. Ophthalmol. 2004;88:1527-1532.
ABSTRACT | FULL TEXT  

Whole body PET/CT imaging for detection of metastatic choroidal melanoma
Finger et al.
Br. J. Ophthalmol. 2004;88:1095-1097.
FULL TEXT  

c-Kit-Dependent Growth of Uveal Melanoma Cells: A Potential Therapeutic Target?
All-Ericsson et al.
IOVS 2004;45:2075-2082.
ABSTRACT | FULL TEXT  

Post-brachytherapy initial tumour regression rate correlates with metastatic spread in posterior uveal melanoma
Kaiserman et al.
Br. J. Ophthalmol. 2004;88:892-895.
ABSTRACT | FULL TEXT  

Prognostic Value of the Disodium Phosphate 32P Uptake Test in Uveal Melanoma: A Long-term Study
Overkleeft et al.
Arch Ophthalmol 2003;121:1398-1403.
ABSTRACT | FULL TEXT  

Uveal Melanoma Survival in Sweden from 1960 to 1998
Bergman et al.
IOVS 2003;44:3282-3287.
ABSTRACT | FULL TEXT  

Trends in Size and Treatment of Recently Diagnosed Choroidal Melanoma, 1987-1997: Findings From Patients Examined at Collaborative Ocular Melanoma Study (COMS) Centers: COMS Report No. 20
Collaborative Ocular Melanoma Study Group
Arch Ophthalmol 2003;121:1156-1162.
ABSTRACT | FULL TEXT  

Heat Shock Protein Expression in the Eye and in Uveal Melanoma
Missotten et al.
IOVS 2003;44:3059-3065.
ABSTRACT | FULL TEXT  

Monosomy 3 in Uveal Melanoma: Correlation with Clinical and Histologic Predictors of Survival
Scholes et al.
IOVS 2003;44:1008-1011.
ABSTRACT | FULL TEXT  

Evidence-Based Estimates of Outcome in Patients Irradiated for Intraocular Melanoma
Gragoudas et al.
Arch Ophthalmol 2002;120:1665-1671.
ABSTRACT | FULL TEXT  

Insulin-like Growth Factor-1 Receptor in Uveal Melanoma: A Predictor for Metastatic Disease and a Potential Therapeutic Target
All-Ericsson et al.
IOVS 2002;43:1-8.
ABSTRACT | FULL TEXT  

Promoter Hypermethylation: A Common Cause of Reduced p16INK4a Expression in Uveal Melanoma
van der Velden et al.
Cancer Res. 2001;61:5303-5306.
ABSTRACT | FULL TEXT  

The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma, III: Initial Mortality Findings: COMS Report No. 18
The Collaborative Ocular Melanoma Study Group
Arch Ophthalmol 2001;119:969-982.
ABSTRACT | FULL TEXT  

Iris Melanomas in Children
Kivela et al.
Arch Ophthalmol 2001;119:925-926.
FULL TEXT  

Assessment of Metastatic Disease Status at Death in 435 Patients With Large Choroidal Melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS Report No. 15
The Collaborative Ocular Melanoma Study Group
Arch Ophthalmol 2001;119:670-676.
ABSTRACT | FULL TEXT  

Overexpression of Epidermal Growth Factor Receptor Restricted to Macrophages in Uveal Melanoma
Scholes et al.
Arch Ophthalmol 2001;119:373-377.
ABSTRACT | FULL TEXT  

Expression of VLA-2, VLA-3, and alpha v integrin receptors in uveal melanoma: association with microvascular architecture of the tumour and prognostic value
Anastassiou et al.
Br. J. Ophthalmol. 2000;84:899-902.
ABSTRACT | FULL TEXT  

Expression of Epidermal Growth Factor Receptor: Risk Factor in Uveal Melanoma
Hurks et al.
IOVS 2000;41:2023-2027.
ABSTRACT | FULL TEXT  

Uveal Melanoma in Young Patients
Singh et al.
Arch Ophthalmol 2000;118:918-923.
ABSTRACT | FULL TEXT  

Combination of Clinical Factors Predictive of Growth of Small Choroidal Melanocytic Tumors
Shields et al.
Arch Ophthalmol 2000;118:360-364.
ABSTRACT | FULL TEXT  

Effects of proton beam irradiation on uveal melanomas: a comparative study of Ki-67 expression in irradiated versus non-irradiated melanomas
Chiquet et al.
Br. J. Ophthalmol. 2000;84:98-102.
ABSTRACT | FULL TEXT  

Antioxidant Pattern in Uveal Melanocytes and Melanoma Cell Cultures
Blasi et al.
IOVS 1999;40:3012-3016.
ABSTRACT | FULL TEXT  

Modelling uveal melanoma
Foss et al.
Br. J. Ophthalmol. 1999;83:588-594.
ABSTRACT | FULL TEXT  

Internal resection of posterior uveal melanomas
Kertes et al.
Br. J. Ophthalmol. 1998;82:1147-1153.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1992 American Medical Association. All Rights Reserved.